It is no longer the current profile. Read the canonical profile and its correction notice.
What this version reported
FDA cites published case reports of melanoma, brain swelling, stimulant-like toxicity and priapism in people who used Melanotan II. No FDA approval is reported in the cited sources, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗
Reader guide in this version
Key takeaway
Melanotan II is a synthetic ring-shaped peptide of seven amino acids, recorded in FDA’s substance registry under the names Melanotan II and MT-II.1 FDA lists Melanotan II among compounding substances that may present significant safety risks, citing published case reports of serious adverse events including melanoma, a brain-swelling syndrome (PRES), a stimulant-like toxic reaction and priapism.2 No FDA approval is reported in the sources reviewed here, and Melanotan II is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,4
At a glance
- What it is
- A synthetic cyclic peptide, N-acetyl-norleucyl-aspartyl-histidyl-D-phenylalanyl-arginyl-tryptophyl-lysinamide closed into a ring between its second and seventh units, according to FDA’s substance registry.1
- FDA status
- No FDA approval is reported in the sources reviewed here. FDA lists Melanotan II among bulk substances whose compounding nominations were withdrawn and that may present significant safety risks.2
- Human evidence
- Published case reports of serious adverse events, cited by FDA. The FDA sources reviewed here do not describe controlled trials of it.2
- Evidence strength
- Limited human data
What is Melanotan II?
Melanotan II is a synthetic peptide of seven units, N-acetyl-norleucine, aspartic acid, histidine, D-phenylalanine, arginine, tryptophan and lysinamide, with a bond closing the chain into a ring, according to FDA’s substance registry.1
FDA’s substance registry also records the name MT-II and a separate entry for its acetate salt.1
How is Melanotan II thought to work?
The FDA sources reviewed here do not describe its mechanism or present studies of its effects.1,2
What do human studies show?
FDA cites published case reports that discuss serious adverse events in people who used Melanotan II, including melanoma, posterior reversible encephalopathy syndrome (a form of brain swelling), sympathomimetic toxidrome (a stimulant-like poisoning) and priapism (a prolonged, painful erection).2
The FDA sources reviewed here do not evaluate whether Melanotan II is effective for any use.2
What the evidence base contains
- Small, short, or incompletely reported human study Published case reports, cited by FDA, of serious adverse events in people who used Melanotan II, including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.2
Evidence-strength label: Limited human data. How this label is assigned
Is Melanotan II FDA-approved?
None of the sources reviewed here reports an approval of Melanotan II by FDA.1,2
FDA’s compounding safety-risk page, current as of April 22, 2026, lists Melanotan II among bulk substances previously in category 2 whose nominations were withdrawn, citing possible immune reactions from aggregation or impurities and the case reports above.2
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Melanotan II is not among them.3,4
Timeline
- FDA’s compounding safety-risk page, as last updated, lists Melanotan II among withdrawn nominations with safety concerns.2
What is still unknown?
How often the serious adverse events in the case reports occur, since case reports cannot measure frequency or prove cause.2
Whether it is effective for any condition, which no FDA source reviewed here has evaluated.2
Sources for this version
- 1Melanotan II substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 2Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 4HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026